Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Bex

Showing results (231-240 of 332) with videos related to

Pageof 34
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 14, 2025
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi studyViktor Grünwald, Axel Bex, Sylvie Rottey, et al.
BJU International|July 12, 2023
Diagnosis, treatment, and survival from kidney cancer: real-world National Health Service England data between 2013 and 2019Samantha Conroy, James W F Catto, Axel Bex, et al.
Abdominal Radiology (New York)|June 22, 2020
Renal biopsies performed before versus during ablation of T1 renal tumors: implications for prevention of overtreatment and follow-upChristiaan V Widdershoven, Brigitte M Aarts, Patricia J Zondervan, et al.
BMC Medicine|October 4, 2019
The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohortTobias Klatte, Kevin M Gallagher, Luca Afferi, et al.
World Journal of Urology|July 18, 2015
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatinElisabeth E Fransen van de Putte, Laura S Mertens, Richard P Meijer, et al.
European Urology|February 4, 2025
Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell CarcinomaJens Bedke, Yasmin Abu Ghanem, Laurence Albiges, et al.
European Urology Oncology|December 12, 2024
Is Frequent Imaging Necessary? Impact of Computed Tomography During Follow-up After Surgical Treatment for Nonmetastatic Renal Cell Carcinoma: A Systematic ReviewLuna van den Brink, Marlin A A Reijerink, Michael M E L Henderickx, et al.
European Urology|December 13, 2022
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell CarcinomaJens Bedke, Laurence Albiges, Umberto Capitanio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2012
Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patientsArjan W Griffioen, Laurie A Mans, Annemarie M A de Graaf, et al.
European Urology|May 17, 2020
Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 PandemicChristopher J D Wallis, Giacomo Novara, Laura Marandino, et al.
Pageof 34

Showing results (231-240 of 332) with videos related to

Sort By:
Pageof 34
European Journal of Cancer (Oxford, England : 1990)|June 14, 2025
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi studyViktor Grünwald, Axel Bex, Sylvie Rottey, et al.
BJU International|July 12, 2023
Diagnosis, treatment, and survival from kidney cancer: real-world National Health Service England data between 2013 and 2019Samantha Conroy, James W F Catto, Axel Bex, et al.
Abdominal Radiology (New York)|June 22, 2020
Renal biopsies performed before versus during ablation of T1 renal tumors: implications for prevention of overtreatment and follow-upChristiaan V Widdershoven, Brigitte M Aarts, Patricia J Zondervan, et al.
BMC Medicine|October 4, 2019
The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohortTobias Klatte, Kevin M Gallagher, Luca Afferi, et al.
World Journal of Urology|July 18, 2015
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatinElisabeth E Fransen van de Putte, Laura S Mertens, Richard P Meijer, et al.
European Urology|February 4, 2025
Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell CarcinomaJens Bedke, Yasmin Abu Ghanem, Laurence Albiges, et al.
European Urology Oncology|December 12, 2024
Is Frequent Imaging Necessary? Impact of Computed Tomography During Follow-up After Surgical Treatment for Nonmetastatic Renal Cell Carcinoma: A Systematic ReviewLuna van den Brink, Marlin A A Reijerink, Michael M E L Henderickx, et al.
European Urology|December 13, 2022
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell CarcinomaJens Bedke, Laurence Albiges, Umberto Capitanio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2012
Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patientsArjan W Griffioen, Laurie A Mans, Annemarie M A de Graaf, et al.
European Urology|May 17, 2020
Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 PandemicChristopher J D Wallis, Giacomo Novara, Laura Marandino, et al.
Pageof 34